Navigation Links
China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
Date:11/12/2012

HONG KONG, Nov. 12, 2012 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in China, today announced the successful completion of the transaction with Cordlife Group Limited (CLGL.SP) ("Cordlife"), a cord blood and tissue banking service provider listed on the Singapore Exchange Securities Trading Limited ("SGX-ST").  The transaction was first announced on August 15, 2012.

As a result of the transaction, CCBC now wholly owns the equity ownership of Guangzhou Municipality Tianhe Nuoya Bio-engineering Co. Ltd. ("Nuoya"), the Company's operating arm in Guangdong province, and Cordlife acquired 7,314,015 ordinary shares of the Company, representing approximately 10% of the Company's issued and outstanding shares.  As of the date of this press release, the Company has 73,140,147 issued shares (inclusive of 100,999 shares being held as treasury shares).

For the purpose of fostering a close alliance and building partnership between CCBC and Cordlife, the board of directors of CCBC has appointed Mr. Jeremy Yee as a non-executive independent director, effective today.  Mr. Yee serves as the Chief Executive Officer of Cordlife and is experienced with developing successful growth strategies in Pan-Asia regions.  Mr. Yee holds a BA (Econ)(Hons) from the University of Manchester and a BCom (Prof Acct) from Murdoch University, as well as a MCom from the University of Sydney, and a MBA from NTU and The University of Chicago Booth School of Business.   

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.  For more information, please visit the Company's website at http://www.chinacordbloodcorp.com.   

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com   

ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516
U.S. Tel: (646) 405-5185
Email: robert.koepp@icrinc.com


'/>"/>
SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
2. China Biologic Products to Report Third Quarter 2012 Financial Results
3. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
4. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
5. Hawaii Tech Asia Takes Hawaii & US Entrepreneurs To China
6. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
7. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
8. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
9. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
10. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
11. China Cord Blood Corporation Files its Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 Regen BioPharma Inc. (OTCQB: ... of Molecular Sciences a team of scientists in ... have demonstrated that expression of NR2F6 in patients with early ... NR2F6 in patient,s cervical cancer tissue as well as in ... "This is an interesting study and the first that I ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... website, http://www.autoreactors.com and online shopping cart. The new website has been ... functionality. These essential digital components allow customers to access detailed product information, read ...
(Date:12/6/2016)... , Dec. 6, 2016 The American Botanical ... adoption of arnica ( Arnica montana ) through ... ABC,s HerbMedPro database, a comprehensive, interactive ... and clinical research data on the uses and ... Naturopathica, a wellness company with healing ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Osteoarthritis Research Society International ... Administration (FDA) to consider OA as a serious disease. As an organization of ... population of OA patients, many of whom may experience progressive disability and decreased ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):